-
Mashup Score: 4Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up Dosing - 2 day(s) ago
Carlyn R Tan, Alice X Wang, David Nemirovsky, Andriy Derkach, Tala Shekarkhand, Issam S. Hamadeh, Kylee H. Maclachlan, Malin L Hultcrantz, Hani Hassoun, Sh
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up Dosing - PubMed - 2 day(s) ago
Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up Dosing
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up Dosing - the MSK experience #mmsm @BloodAdvances @MSKCancerCenter @MSK_DeptOfMed @CarlynRTanMD et al. https://t.co/KFhyLAz76z
-
-
Mashup Score: 0
The absence of a PFS and OS benefit in the transplant arm was consistent across key subgroups in the phase 3 GMMG ReLApsE trial.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
The median OS was 67.1 months (95% CI, 59.2-85.4) in the transplant arm vs 62.7 months (95% CI, 49.6-86.0) with continuous lenalidomide/dexamethasone in the control arm (HR, 0.89; 95% CI, 0.66-1.20; P = .44). #mmsm https://t.co/02cqBL7Aa5
-
-
Mashup Score: 4
Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma. #mmsm | @PennMedicine @PennCancer @AlGarfall https://t.co/lF6v4xTXA0
-
-
Mashup Score: 0
Updated findings from the MAIA trial support the use of frontline daratumumab plus lenalidomide/dexamethasone in transplant-ineligible NDMM.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
After a median follow-up of 64.5 months across the ITT population, the median PFS was 61.9 months with D-Rd vs 34.4 months with Rd (HR, 0.55; 95% CI, 0.45-0.67; P <.0001). #mmsm https://t.co/O654xE5G2S
-
-
Mashup Score: 1Clinician, Multiple Myeloma Program - Boston, Massachusetts - 6 day(s) ago
The Dana-Farber Cancer Institute is seeking a full-time medical oncologist for a Clinical Investigator position in our Multiple Myeloma Program.
Source: www.nejmcareercenter.orgCategories: General Medicine News, Hem/OncsTweet-
RT @IrenemGhobrial: We are hiring to a myeloma and early precursor position. https://t.co/WdJjA1Rezu #MMSM
-
-
Mashup Score: 0Mejoras en la supervivencia global del mieloma: ¿de dónde proviene este tiempo adicional? - 23 day(s) ago
¡Los mejores tratamientos mejoran la supervivencia!
Source: rafaelfonseca.substack.comCategories: General Medicine News, Hem/OncsTweet-
Mejoras en la supervivencia global del mieloma: ¿de dónde proviene este tiempo adicional? #mmsm https://t.co/hFqrJvzan9 https://t.co/H9poG7UhB6
-
-
Mashup Score: 0
During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to CAR T-cell therapy in multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Muhammad Umair Mushtaq, MD, (@mumairmushtaq) discussed managing long-term toxicity concerns related to CAR T-cell therapy in multiple myeloma. #mmsm | @KUMedCenter https://t.co/HAXOlLapZS https://t.co/iNdmaSMLXS
-
-
Mashup Score: 1FDA Accepts Linvoseltamab BLA for Review in R/R Multiple Myeloma - 28 day(s) ago
Efficacy results from the phase 1/2 LINKER-MM1 trial evaluating linvoseltamab in relapsed or refractory multiple myeloma support the decision.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
The FDA has accepted for review a biologics license application resubmission for linvoseltamab as a treatment for adult patients with relapsed or refractory multiple myeloma. #mmsm | @FDAOncology https://t.co/BicG70gLCC
-
-
Mashup Score: 3Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma | Regeneron Pharmaceuticals Inc. - 28 day(s) ago
Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10 , 2025 TARRYTOWN, N.Y. , Feb. 11, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals , Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for
Source: investor.regeneron.comCategories: General Medicine News, Oncologists1Tweet-
🚨 NEWS 🚨 @US_FDA accepts for review the BLA for linvoseltamab, a BCMA-directed bsAb, for the treatment of RRMM with ≥4 prior LOTs or ≥3 prior LOTs and is refractory to the last line, based on data from the LINKER-MM1 trial. Read more: https://t.co/GhQtYtiGqM #mmsm… https://t.co/K9cT161K1p https://t.co/u61tv3SU9a
-
Congrats @CarlynRTanMD et al! We always talk about spacing out #MMsm bsAb to Q4W etc to ⬇️ infxns, dysgeusia, etc. One counterargument was that doing so would require repeat SUD per USPI... but thanks to this 👇🏼 in @BloodAdvances, we know it doesn't! https://t.co/PvCj5rdhwY https://t.co/uXgXQQDjJg